





Attractive Calls in Medical Device Leader as Group Sets Up Well for Earnings

TRADE SNAPSHOT


TICKER	ABT						
HORLK	אטו						
SECURITY	Abbott Labs						
SECTOR	Healthcare – Medical Devices						
CURRENT PRICE	\$107						
LONG/SHORT	Long						
TARGET	\$116						
STOP	\$101						
TIMEFRAME	5 Months						

Trading Strategy: Long ABT January \$110 Calls at \$5.20 or Better

Net Debit/Credit: Debit \$5.20

Profitability Zone: ABT Above \$115.20 on January OpEx

Options Volatility / Trade Simulator View:





Technical Analysis: ABT is bull flagging above its 200-MA on the daily but the weekly shows a long bottoming base set-up just under VWAP off the highs and the 38.2% retracement, needing to clear those \$110.25 and \$111.85 levels respectively to open up a much stronger push to 115-117.



Fundamental Analysis: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. ABT has a market cap of \$187B and trades 23X Earnings, 19X EBITDA and 4.5X Sales with a 4.7% FCF yield. Forecasts see revenues accelerating the next few quarters along with profits. ABT should see 10% organic growth this quarter ex-Covid testing led by Libre. The >\$7B cardiac ablation market is on the cusp of a technological shift towards a new technology (pulsed field ablation). The pacemaker market is on the cusp of an accelerated shift to leadless technologies (supported by strong Aveir data at HRS and expansion into dual chamber pacing). ABT also has a strong balance sheet and opportunities for capital deployment. Analysts have an average target of \$124 with short interest under 1% of the float. Evercore added to Tactical Outperform this week and has a \$120 target.

Options Activity:

Date	Ticker	Contract	Volume	Price	OI	Delta	IV	Premium	Last	Current OI ▽	△ Price %
06-29-2023	ABT	ABT 100 21 JUL 23 108 CALL	4,020	\$1.86	699	0.47	18.56%	\$715,560	\$1.14	4,769	▼ 38.71%
11-01-2022	ABT	ABT 100 19 JAN 24 110 CALL	892	\$8.75	768	0.44	29.35%	\$798,340	\$5.15	4,477	▼ 41.14%
02-22-2023	ABT	ABT 100 19 JAN 24 110 CALL	1,965	\$7.32	1,634	0.47	23.42%	\$1,483,575	\$5.15	4,477	▼ 29.64%
12-01-2022	ABT	ABT 100 19 JAN 24 105 PUT	1,500	\$8.6	998	-0.38	24.53%	\$1,312,500	\$4.53	4,344	▼ 47.38%
06-29-2023	ABT	ABT 100 21 JUL 23 108 PUT	4,001	\$2.39	146	-0.52	21.66%	\$1,016,254	\$2.62	4,269	△ 9.62%
06-08-2023	ABT	ABT 100 17 NOV 23 90 PUT	2,637	\$1.89	1,029	-0.19	24.22%	\$511,578	\$0.77	3,226	△ 58.99%
04-12-2023	ABT	ABT 100 19 JAN 24 90 PUT	1,000	\$3.5	1,522	-0.22	27.42%	\$360,000	\$1.31	3,003	△ 62.71%
09-19-2022	ABT	ABT 100 19 JAN 24 80 PUT	1,000	\$3.95	40	-0.18	29.99%	\$420,000	\$0.58	2,517	△ 85.44%
04-19-2023	ABT	ABT 100 17 NOV 23 100 PUT	600	\$2.83	249	-0.21	23.51%	\$155,400	\$2.25	2,167	▼ 20.67%
04-20-2023	ABT	ABT 100 17 NOV 23 100 PUT	1,116	\$2.85	760	-0.22	23.42%	\$323,640	\$2.25	2,167	△ 21.23%
06-01-2023	ABT	ABT 100 17 NOV 23 105 CALL	1,305	\$5.67	409	0.51	21.83%	\$756,900	\$6.5	1,582	△ 14.64%
03-09-2023	ABT	ABT 100 21 JUN 24 80 PUT	800	\$3.1	10	-0.17	27.59%	\$276,000	\$1.32	1,080	△ 57.42%

Potential Catalysts: Earnings 7/20; Capital Deployment News

Disclaimer:

Not Investment Advice or Recommendation

Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a recommendation. The Author may or may not take positions in any of the names mentioned, and is not obligated to disclose positions, nor position sizes.

Content is for informational and educational purposes only, and is not to be construed as specific investment advice or recommendations. You alone will need to evaluate the merits and risks associated with the use of this content. Decisions based on information provided are your sole responsibility, and before making any decision on the basis of this information, you should consider (with or without the assistance of a financial and/or securities adviser) whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek qualified professional financial advice regarding the suitability of investing in any securities or following any investment strategies.

No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security. Nothing constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, OptionsHawk has not taken into account the investment needs, objectives and financial circumstances of any particular investor. This information does not consider the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors

For example, and, as always, be aware that market timing and conditions may materially affect trades of this nature: The above is an example of a trade idea, but you must be aware of the risks of trading. As we have disclosed, we are not licensed, and we are not giving specific securities advice for your portfolio. We are merely providing examples and education of strategies. We always advise people to get professional advice, and we are not recommending any particular trade or security, or soliciting any trade or security.